Skip to content

Author

C. Barrios

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial

Numerically higher 3-year EFS and DFS rates with atezolizumab were seen in patients with PD-L1–negative status, HR-positive status, and stage T2 disease, and Numerical DFS improvements with atezolizumab occurred regardless of pCR.

J. Huober, C. Barrios, N. Niikura et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.